Clinical Research Directory

Inclusion Criteria: * Age of at least 50 years. * DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR * DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR * Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR * DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR * Deteriorating Diabetes: DM with \>2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance * ECOG Performance Status of 0-1. * No known contraindications to MRI examination or gadolinium contrast. * Willing to undergo MRI and screening for metal implants or metal injury. * Recent BUN and Cr * Estimated GFR (eGFR) must be greater than 30 mL/min. * Ability to provide informed consent. * Willing to return to study site for all study assessments. Exclusion Criteria: * Prior history of pancreatic cancer. * Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years. * Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years). * Hereditary pancreatitis. * eGFR \< 30 mL/min. * Contraindication to MRI examination or gadolinium contrast. * Pregnant or nursing women. * Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.